0001567619-19-021875.txt : 20191119
0001567619-19-021875.hdr.sgml : 20191119
20191119164653
ACCESSION NUMBER: 0001567619-19-021875
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191115
FILED AS OF DATE: 20191119
DATE AS OF CHANGE: 20191119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ende Eric J
CENTRAL INDEX KEY: 0001494386
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37977
FILM NUMBER: 191231825
MAIL ADDRESS:
STREET 1: C/O MATINAS BIOPHARMA HOLDINGS, INC.
STREET 2: 1545 ROUTE 206 SOUTH, SUITE 302
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC
CENTRAL INDEX KEY: 0001012477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
STREET 2: BALLYCOOLIN
CITY: DUBLIN
STATE: L2
ZIP: 15
BUSINESS PHONE: 636-449-1830
MAIL ADDRESS:
STREET 1: 16640 CHESTERFIELD GROVE ROAD
STREET 2: SUITE 200
CITY: CHESTERFIELD
STATE: MO
ZIP: 63005
FORMER COMPANY:
FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA
DATE OF NAME CHANGE: 19960422
4
1
doc1.xml
FORM 4
X0306
4
2019-11-15
0
0001012477
AVADEL PHARMACEUTICALS PLC
AVDL
0001494386
Ende Eric J
C/O AVADEL PHARMACEUTICALS PLC
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
DUBLIN
L2
15
IRELAND
1
0
0
0
ADSs
2019-11-15
4
P
0
10000
4.9762
A
37900
D
Stock Option (right to buy)
1.49
2029-05-22
ADSs
8057
8057
D
Stock Option (right to buy)
2.03
2029-08-07
ADSs
60000
60000
D
The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.94 to $4.98, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 01/31/2019; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.
Options are exercisable as to 2,685 shares, 2,686 shares and 2,686 shares on May 22, 2020, May 22, 2021 and May 22, 2022, respectively.
Options become exercisable as to 20,000 ADSs on each of the first three anniversaries after the 08/07/2019 grant date.
/s/ Phillandas T. Thompson, as attorney-in-fact for Eric J. Ende
2019-11-19